T. Rowe Price Associates
LRMR icon

T. Rowe Price Associates’s Larimar Therapeutics LRMR Stock Holding History

T. Rowe Price Associates’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$167K Buy
54,629
+19,861
+57% +$78.9K ﹤0.01% 3054
2026
Q1 		$157K Buy
34,768
+5,760
+20% +$23K ﹤0.01% 2903
2025
Q4 		$111K Buy
29,008
+6,038
+26% +$23.5K ﹤0.01% 2931
2025
Q3 		$75K Buy
22,970
+1,669
+8% +$6.26K ﹤0.01% 2969
2025
Q2 		$62K Buy
21,301
+4,991
+31% +$11.6K ﹤0.01% 2974
2025
Q1 		$36K Buy
16,310
+858
+6% +$2.71K ﹤0.01% 2965
2024
Q4 		$60K Buy
15,452
+1,992
+15% +$13.1K ﹤0.01% 2907
2024
Q3 		$89K Hold
13,460
– – ﹤0.01% 2842
2024
Q2 		$98K Buy
+13,460
New +$103K ﹤0.01% 2762
2019
Q3 		– Sell
-3,901
Closed -$56K – 2536
2019
Q2 		$56K Sell
3,901
-42
-1% -$1.12K ﹤0.01% 2510
2019
Q1 		$130K Sell
3,943
-68,617
-95% -$3.52M ﹤0.01% 2449
2018
Q4 		$4.31M Sell
72,560
-31,147
-30% -$3.07M ﹤0.01% 1420
2018
Q3 		$14.5M Buy
+103,707
New +$12.6M ﹤0.01% 1308
2017
Q1 		– Sell
-5,910
Closed -$226K – 2585
2016
Q4 		$226K Sell
5,910
-11
-0.2% -$446 ﹤0.01% 2348
2016
Q3 		$235K Hold
5,921
– – ﹤0.01% 2305
2016
Q2 		$426K Sell
5,921
-946
-14% -$74.8K ﹤0.01% 2024
2016
Q1 		$550K Sell
6,867
-1,997
-23% -$158K ﹤0.01% 1930
2015
Q4 		$669K Sell
8,864
-28,418
-76% -$4.56M ﹤0.01% 1834
2015
Q3 		$14.3M Sell
37,282
-5,351
-13% -$2.41M ﹤0.01% 1207
2015
Q2 		$17.7M Sell
42,633
-1,747
-4% -$731K ﹤0.01% 1174
2015
Q1 		$21.1M Buy
+44,380
New +$21.1M ﹤0.01% 1113

Other funds holding LRMR

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

T. Rowe Price Associates's LRMR Position: Q2 2026 in Review

T. Rowe Price Associates increased its Larimar Therapeutics (LRMR) stake by 57% in Q2 2026, buying an estimated $78.9K and bringing the position to 54,629 shares worth $167K. The position accounts for ﹤0.01% of the portfolio, ranked #3054.

T. Rowe Price Associates first reported a position in LRMR in Q1 2015 and has held it in 21 quarters since. The position peaked at $21.1M in Q1 2015. 163 funds tracked by Wall St. Rank hold LRMR as of Q2 2026.

  • T. Rowe Price Associates held 54,629 shares of Larimar Therapeutics worth $167K as of Q2 2026.
  • T. Rowe Price Associates bought 19,861 Larimar Therapeutics shares in Q2 2026, an estimated $78.9K.
  • Larimar Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #3054 holding.
  • T. Rowe Price Associates first reported a position in Larimar Therapeutics in Q1 2015 and has held it in 21 quarters since.
  • T. Rowe Price Associates's Larimar Therapeutics position peaked at $21.1M in Q1 2015.
  • 163 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.